LONDON: In a company announcement, Autolus Therapeutics plc (Nasdaq: AUTL), a trailblazer in programmed T cell therapies, has released its operational and financial results for the year ending December 31, 2023. The company, which is in the clinical stage, revealed a cash reserve of $239.6 million, a notable decrease from the previous year’s $382.4 million.…